Related Experiment Videos
Decrease of intestinal P-glycoprotein activity by 2n-propylquinoline, a new oral treatment for visceral leishmaniasis
A M Belliard1, C Leroy, H Banide
1Laboratoire de Pharmacie Clinique-Physiologie, UPRES 2706, Faculté de Pharmacie, 92296, Châtenay-Malabry Cedex, France.
Experimental Parasitology
|June 18, 2003
Summary
2n-propylquinoline (2nPQ) shows promise in inhibiting P-glycoprotein (P-gp) activity, a key factor in Leishmania drug resistance. This oral anti-leishmanial drug could offer a new strategy against multi-drug-resistant visceral leishmaniasis.
Area of Science:
- Pharmacology
- Parasitology
- Drug Discovery
Background:
- Current visceral leishmaniasis treatments pose toxicity and drug resistance challenges.
- P-glycoprotein (P-gp) activity in Leishmania contributes to multi-drug resistance.
- There is a need for novel, effective anti-leishmanial therapies.
Purpose of the Study:
- To investigate the potential of 2n-propylquinoline (2nPQ) to inhibit P-gp activity.
- To evaluate 2nPQ's efficacy as an oral anti-leishmanial agent.
- To explore 2nPQ's role in overcoming drug resistance in Leishmania.
Main Methods:
- Utilized rat everted gut sacs and human intestinal Caco-2 cell lines.
- Assessed 2nPQ's effect on P-gp activity using known P-gp substrates (rhodamine 123, digoxin) and inhibitors (cyclosporin A, verapamil).
- Tested 2nPQ's inhibitory effects across two different species.
Main Results:
- 2nPQ demonstrated significant inhibitory effects on P-gp activity.
- The inhibition was observed with multiple P-gp substrates and inhibitors.
- 2nPQ showed consistent P-gp inhibitory effects in both tested species and models.
Conclusions:
- 2nPQ exhibits potent P-gp inhibitory activity, suggesting a mechanism to combat Leishmania multi-drug resistance.
- This oral agent could be valuable alone or in combination therapies for visceral leishmaniasis.
- 2nPQ may help manage intestinal P-gp activity in human kala-azar patients.